4D Pharma restates first-half earnings due to accounting change

  • 📰 MarketWatch
  • ⏱ Reading Time:
  • 32 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 16%
  • Publisher: 97%

日本 ニュース ニュース

日本 最新ニュース,日本 見出し

The London- and U.S.-listed pharmaceutical company said the warrants and units should be recorded as derivative liabilities and not equity instruments under...

A previously published version of this story incorrectly stated that 4D’s loss widened in the first paragraph, and numbers were transposed in the fourth and fifth paragraphs. The story has been corrected.

The... A previously published version of this story incorrectly stated that 4D’s loss widened in the first paragraph, and numbers were transposed in the fourth and fifth paragraphs. The story has been corrected. The London- and U.S.-listed pharmaceutical company LBPS DDDD said the warrants and units should be recorded as derivative liabilities and not equity instruments under both IFRS and U.S. GAAP accounting standards.Under the change, pretax loss for the half year ended June 30 was 50.1 million pounds compared with a previously reported loss of GBP57.0 million and a loss of GBP15.7 million for the comparable half.

 

コメントありがとうございます。コメントは審査後に公開されます。
このニュースをすぐに読めるように要約しました。ニュースに興味がある場合は、ここで全文を読むことができます。 続きを読む:

 /  🏆 3. in JP

日本 最新ニュース, 日本 見出し